LLS News Network

News and Information from The Leukemia & Lymphoma Society

Survey Reveals Striking Lack of Knowledge of Major Cancer Killer

View full multimedia release here.  Rye Brook, NY (August 31, 2017) – Blood cancers are the third leading cause of cancer deaths in the U.S. However, many Americans are unaware of the impact of these cancers, including leukemia, lymphoma and myeloma, which affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. A new survey commissioned by The Leukemia &...

LLS Investment Pays Off: FDA Approves Immunotherapy for Blood Can...

Rye Brook, N.Y. (August 30, 2017) – Today heralds a new era in cancer treatment with the U.S. Food and Drug Administration (FDA) approval of a new, cutting-edge gene therapy that reprograms a patient’s immune system to find and kill cancer cells.  This highly personalized therapy known as Kymriah (previously CTL019 or tisagenlecleucel-T) signifies the promise of CAR (chimeric antigen receptor) T-cell im...

FDA Approval: LLS Applauds New Advance for Acute Lymphoblastic Le...

RYE BROOK, N.Y. (August 17, 2017) – The Leukemia & Lymphoma Society (LLS) applauds today’s approval by the U.S. Food and Drug Administration (FDA) of inotuzumab ozogamicin (Besponsa®) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This year alone, it is estimated that almost 6,000 people in the United States will be diagnosed with ALL. Thi...

More than 20 Years Helping Cancer Patients and Saving Lives

See multimedia release here.  RYE BROOK, N.Y. (August 8, 2017) – Where can I get good information about my cancer and treatments? Should I get a second opinion? Is there anyone I can talk with who has been through this? Where can I get financial assistance to help cover the cost of my treatment? How do I talk with my loved ones and children about my disease? These are just a few of the hundreds of questions...

LLS Applauds Another Advance for Blood Cancer Patients

August 3, 2017 (Rye Brook, NY)  - The Leukemia & Lymphoma Society (LLS) applauds the  U.S. Food and Drug Administration (FDA) approval today of CPX-351 (VyxeosTM), an innovative combination of two chemotherapy drugs being used to treat two high-risk subgroups of acute myeloid leukemia (AML) patients. After more than four decades of little progress in treating AML, this approval marks the third drug appr...

LLS Teams Up with SAGERSTRONG Foundation To Fight Blood Cancers

View full multimedia release here (Washington, D.C., May 3, 2017) – The Leukemia & Lymphoma Society (LLS) and the SAGERSTRONG Foundation announced yesterday they are teaming up to raise funds to fight blood cancers, the third leading cause of cancer deaths in the United States. Louis J. DeGennaro, Ph.D., LLS president and CEO, and Stacy Sager, president of the SAGERSTRONG Foundation, jointly made the announc...

The Leukemia & Lymphoma Society Statement on Proposed Cuts to NIH...

The Leukemia & Lymphoma Society (LLS) firmly opposes the Administration’s proposed budget, which reduces the funding for the National Institutes of Health (NIH) by $5.8 billion. These cuts risk derailing decades of advancement in the diagnosis, understanding and treatment of deadly blood cancers. LLS is calling upon members of Congress to reject these proposed cuts and increase funding for the NIH in future app...

Majority of 26,000 Calls to LLS Reflect Patient Financial Stress

(Rye Brook, NY – May 2, 2017) – The rising cost of treatment and care for blood cancer patients has reached a boiling point, according to The Leukemia & Lymphoma Society (LLS), with an increasing number of patients foregoing their medications or reducing the dosage or frequency of their doctor‐prescribed treatments solely for cost reasons. In 2016, LLS’s free Information Resource Center received more than...

Precision Medicine and Immunotherapy Hold Promise, Cost of Care G...

View full multimedia release here. (Rye Brook, NY – May 3, 2017) – The nation’s leading experts on blood cancers and healthcare policy convened yesterday in Washington, D.C. to discuss the ever-increasing cost barriers that patients and their families face to access high-quality care, as well as discuss cutting-edge blood cancer research and treatments. The event was organized by The Leukemia & Lymp...

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: